Real-world multicentre analysis of neoadjuvant immunotherapy and chemotherapy in localized or oligometastatic non-small cell lung cancer (KOMPASSneoOP).
Martin FaehlingHanno WitteMartin SebastianMatthias UlmerRainer SätzlerKonrad SteinestelWolfgang M BrücklGeorg EversChristian Meyer Zum BüschenfeldeAnnalen BleckmannPublished in: Therapeutic advances in medical oncology (2022)
To our knowledge, this study encompassed the largest NSCLC real-world cohort treated with neoadjuvant immuno(chemo)therapy to date. In routine clinical practice, resection after neoadjuvant immuno(chemo)therapy is feasible in patients with locally resectable NSCLC, including oligometastatic disease. In line with clinical trials, we found MPR in more than two-thirds of patients. Early data show encouraging survival.
Keyphrases
- locally advanced
- rectal cancer
- clinical practice
- squamous cell carcinoma
- clinical trial
- radiation therapy
- small cell lung cancer
- end stage renal disease
- newly diagnosed
- lymph node
- ejection fraction
- healthcare
- advanced non small cell lung cancer
- photodynamic therapy
- peritoneal dialysis
- prognostic factors
- cross sectional
- electronic health record
- cancer therapy
- randomized controlled trial
- patient reported outcomes
- brain metastases
- drug delivery
- data analysis
- smoking cessation
- replacement therapy
- patient reported